The association between measures of progression and survival in castrate-metastatic prostate cancer Journal Article
| Authors: | Scher, H. I.; Warren, M.; Heller, G. |
| Article Title: | The association between measures of progression and survival in castrate-metastatic prostate cancer |
| Abstract: | Purpose: To explore the association between progression-free survival and overall survival time in patients with castration-resistant prostate cancer treated with microtubule-targeted therapies. Experimental Design: We retrospectively studied patients treated in three trials evaluating a taxane or an epothilone for progressive castration-resistant prostate cancer. Study subjects were 98 patients with bone metastases; 63 of them also had soft tissue lesions. All scans were reviewed independently. Associations of radiographic progression-free survival and prostate-specific antigen (PSA) progression-free survival with survival time were measured using Kendall's τ, adjusted for right censoring. A smoothing procedure was applied to estimate Kendall's τ within each neighborhood of the follow-up process. Results: The overall associations between progression-free survival time and overall survival time were moderate: 0.4 for radiographic progression-free survival and 0.33 for PSA progression-free survival. The association between radiographic progression-free survival and overall survival was weakest early in the follow-up process, whereas the PSA association was weakest when the progression-free survival - related event (PSA progression, death, or censoring) occurred after 6 months from the start of treatment. Conclusions: Current measures of progression-free survival time for men with castration-resistant prostate cancer are not strongly concordant with survival time. Factors that attenuate the association include interval censoring and the discontinuation of therapy early in the follow-up due to imaging changes that may not reflect true failure of the treatment. For radiographic progression-free survival, the association may be increased by requiring confirmation of progression with a second scan, as is routinely done when assessing response. © 2007 American Association for Cancer Research. |
| Keywords: | cancer survival; controlled study; bone neoplasms; disease-free survival; survival rate; retrospective studies; major clinical study; cancer growth; antineoplastic agents; bone metastasis; follow up; adenocarcinoma; prostate specific antigen; carboplatin; docetaxel; prostate cancer; prostate-specific antigen; prostatic neoplasms; disease progression; androgen antagonists; radiography; taxoids; castration; antineoplastic agents, hormonal; microtubule; clinical trials; soft tissue neoplasms; epothilones; epothilone b; estramustine |
| Journal Title: | Clinical Cancer Research |
| Volume: | 13 |
| Issue: | 5 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2007-03-01 |
| Start Page: | 1488 |
| End Page: | 1492 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-06-1885 |
| PUBMED: | 17332293 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 30" - "Export Date: 17 November 2011" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work